Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease | Zendy

Hyekyung Yang | Zendy; CheolYoung Park | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease

Author(s) -

Hyekyung Yang,

CheolYoung Park

Publication year - 2018

Publication title -

journal of korean diabetes

Language(s) - English

Resource type - Journals

eISSN - 2714-0547

pISSN - 2233-7431

DOI - 10.4093/jkd.2018.19.2.88

Subject(s) - medicine , nonalcoholic fatty liver disease , diabetes mellitus , fatty liver , disease , intensive care medicine , endocrinology

Nonalcoholic fatty liver disease (NAFLD) is more prevalent in diabetic patients than in non-diabetic subjects, because the two diseases share a common pathophysiological mechanism. Associated abnormalities can be observed from the pre-diabetic stage. Lifestyle intervention, including diet, exercise, and weight loss, is the primary recommended therapy for NAFLD. Among the therapeutic drugs for NAFLD treatment, anti-diabetic agents are aimed at improving or slowing the progression of NAFLD in addition to lowering blood glucose. In this paper, we systemically review the evidence surrounding antidiabetic medications and their ability to improve disease progression in patients with NAFLD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research